William B Parker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11484726/publications.pdf

Version: 2024-02-01

44 papers	2,430 citations	331670 21 h-index	265206 42 g-index
45 all docs	45 docs citations	45 times ranked	2484 citing authors

#	Article	IF	Citations
1	Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. Chemical Reviews, 2009, 109, 2880-2893.	47.7	484
2	Metabolism and mechanism of action of 5-fluorouracil. , 1990, 48, 381-395.		373
3	Metabolism and antiviral activity of ribavirin. Virus Research, 2005, 107, 165-171.	2.2	197
4	In VivoGene Therapy of Cancer withE. coliPurine Nucleoside Phosphorylase. Human Gene Therapy, 1997, 8, 1637-1644.	2.7	110
5	Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochemical and Biophysical Research Communications, 1989, 161, 393-398.	2.1	105
6	Metabolism and Metabolic Actions of 6-Methylpurine and 2-Fluoroadenine in Human Cells. Biochemical Pharmacology, 1998, 55, 1673-1681.	4.4	103
7	Anti-Aids Agents, 1. Isolation and Characterization of Four New Tetragalloylquinic Acids as a New Class of HIV Reverse Transcriptase Inhibitors from Tannic Acid. Journal of Natural Products, 1989, 52, 762-768.	3.0	98
8	Lymphoma Chemovirotherapy: CD20-Targeted and Convertase-Armed Measles Virus Can Synergize with Fludarabine. Cancer Research, 2007, 67, 10939-10947.	0.9	86
9	An Immunocompetent Murine Model for Oncolysis with an Armed and Targeted Measles Virus. Molecular Therapy, 2007, 15, 1991-1997.	8.2	79
10	Structural Basis for Substrate Specificity of Escherichia coli Purine Nucleoside Phosphorylase. Journal of Biological Chemistry, 2003, 278, 47110-47118.	3.4	76
11	Antitumor activity of 2-fluoro-2â€²-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Therapy, 2003, 10, 23-29.	4.6	74
12	Cell to Cell Contact Is Not Required for Bystander Cell Killing by Escherichia coli Purine Nucleoside Phosphorylase. Journal of Biological Chemistry, 1998, 273, 2322-2328.	3.4	59
13	Excellent In vivo Bystander Activity of Fludarabine Phosphate against Human Glioma Xenografts that Express the Escherichia coli Purine Nucleoside Phosphorylase Gene. Cancer Research, 2004, 64, 6610-6615.	0.9	54
14	Activity of Ribavirin against Hantaan Virus Correlates with Production of Ribavirin-5â€²-Triphosphate, Not with Inhibition of IMP Dehydrogenase. Antimicrobial Agents and Chemotherapy, 2007, 51, 84-88.	3.2	45
15	Designer Gene Therapy Using an Escherichia coli Purine Nucleoside Phosphorylase/Prodrug System. Chemistry and Biology, 2003, 10, 1173-1181.	6.0	43
16	Gene Therapy of Cancer: Activation of Nucleoside Prodrugs withE. coliPurine Nucleoside Phosphorylase. Nucleosides & Nucleotides, 1999, 18, 745-757.	0.5	42
17	Metabolism of 4â€²-thio-Î²-d-arabinofuranosylcytosine in CEM cells. Biochemical Pharmacology, 2000, 60, 1925-1932.	4.4	35
18	A Long-Acting Suicide Gene Toxin, 6-Methylpurine, Inhibits Slow Growing Tumors after a Single Administration. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 1280-1284.	2.5	34

#	Article	IF	Citations
19	PNP Anticancer Gene Therapy. Current Topics in Medicinal Chemistry, 2005, 5, 1259-1274.	2.1	32
20	Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5â€²-triphosphates of various anti-HIV nucleoside analogs. Antiviral Research, 1993, 22, 295-308.	4.1	30
21	In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer Chemotherapy and Pharmacology, 2012, 70, 321-329.	2.3	27
22	Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E.Âcoli purine nucleoside phosphorylase: Palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides. European Journal of Medicinal Chemistry, 2012, 47, 167-174.	5.5	27
23	Antibiotic-Mediated Chemoprotection Enhances Adaptation ofE. coliPNP for Herpes Simplex Virus-Based Glioma Therapy. Human Gene Therapy, 2005, 16, 339-347.	2.7	23
24	Phosphorylation of 4â€²-thio-Î²-d-Arabinofuranosylcytosine and Its Analogs by Human Deoxycytidine Kinase. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 1314-1322.	2.5	21
25	Characterization of a novel inhibitor of human DNA polymerases: 3,4,5-tri-O-galloylquinic acid. Biochemical Pharmacology, 1989, 38, 3759-3765.	4.4	18
26	Lack of mitochondrial toxicity in CEM cells treated with carbovir. Antiviral Research, 1997, 34, 131-136.	4.1	18
27	The metabolism of 2-methyladenosine in Mycobacterium smegmatis. Microbiology (United Kingdom), 2002, 148, 289-295.	1.8	16
28	Metabolism of 2-methyladenosine in Mycobacterium tuberculosis. Tuberculosis, 2004, 84, 327-336.	1.9	14
29	DESIGN AND EVALUATION OF 5â€²-MODIFIED NUCLEOSIDE ANALOGS AS PRODRUGS FOR AN E. COLI PURINE NUCLEOSIDE PHOSPHORYLASE MUTANT. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 387-392.	1.1	13
30	Long intracellular retention of 4â€²-thio-arabinofuranosylcytosine 5â€²-triphosphate as a critical factor for the anti-solid tumor activity of 4â€²-thio-arabinofuranosylcytosine. Cancer Chemotherapy and Pharmacology, 2006, 57, 772-780.	2.3	12
31	The Crystal Structure ofStreptococcus pyogenesUridine Phosphorylase Reveals a Distinct Subfamily of Nucleoside Phosphorylases. Biochemistry, 2011, 50, 6549-6558.	2.5	12
32	Synthesis and anti-Hantaan virus activity of N1-3-fluorophenyl-inosine. Antiviral Research, 2009, 83, 80-85.	4.1	10
33	6-Substituted Derivatives of Carbovir: Anti-HIV Activity. Nucleosides & Nucleotides, 1995, 14, 1703-1708.	0.5	8
34	6-Methylpurine derived sugar modified nucleosides: Synthesis and evaluation of their substrate activity with purine nucleoside phosphorylases. Bioorganic Chemistry, 2016, 65, 9-16.	4.1	8
35	Intratumoral generation of 2â€fluoroadenine to treat solid malignancies of the head and neck. Head and Neck, 2019, 41, 1979-1983.	2.0	7
36	Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors. Current Pharmaceutical Design, 2018, 23, 7003-7024.	1.9	6

#	Article	IF	Citations
37	Interference with HIV-1 reverse transcriptase-catalyzed DNA chain elongation by the 5â€²-triphosphate of the carbocyclic analog of 2â€²-deoxyguanosine. Antiviral Research, 1992, 19, 325-332.	4.1	5
38	6-Methylpurine derived sugar modified nucleosides: Synthesis and inÂvivo antitumor activity in D54 tumor expressing M64V- Escherichia coli purine nucleoside phosphorylase. European Journal of Medicinal Chemistry, 2016, 108, 616-622.	5.5	5
39	The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 85, 573-583.	2.3	5
40	Metabolism of O⁶-Propyl and N⁶-Propyl-carbovir in CEM Cells. Nucleosides, Nucleotides and Nucleic Acids, 2000, 19, 795-804.	1.1	4
41	Regioselective Metalation of 6-Methylpurines: Synthesis of Fluoromethyl Purines and Related Nucleosides for Suicide Gene Therapy of Cancer. Nucleosides, Nucleotides and Nucleic Acids, 2009, 28, 642-656.	1.1	4
42	Structure of grouper iridovirus purine nucleoside phosphorylase. Acta Crystallographica Section D: Biological Crystallography, 2010, 66, 155-162.	2.5	4
43	Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology. , 2017, , 261-286.		2
44	PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS. Transactions of the American Clinical and Climatological Association, 2016, 127, 59-70.	0.5	2